Treating multiple sclerosis with monoclonal antibodies: A 2010 update

Expert Review of Neurotherapeutics

Volumn 10, Issue 5, 2010, Pages 791-809

  Buttmann, Mathias ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Alemtuzumab; Daclizumab; LY2127399; Multiple sclerosis; Natalizumab; Ocrelizumab; Ofatumumab; Progressive multifocal leukoencephalopathy; Rituximab; Ustekinumab

Indexed keywords

ALEMTUZUMAB; ARZERRA; BETA1A INTERFERON; CLADRIBINE; DACLIZUMAB; FINGOLIMOD; GLATIRAMER; LY 2127399; MONOCLONAL ANTIBODY; NATALIZUMAB; OCRELIZUMAB; OFATUMUMAB; PLACEBO; RECOMBINANT BETA INTERFERON; RITUXIMAB; UNCLASSIFIED DRUG; USTEKINUMAB;

CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DIZZINESS; DRUG SAFETY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NAUSEA; NONHUMAN; PAIN; PNEUMONIA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RASH; REVIEW; RHEUMATOID ARTHRITIS; SKIN DISEASE; THROAT IRRITATION; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; LEUKOENCEPHALOPATHIES; MULTIPLE SCLEROSIS;

EID: 77951843688     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.38     Document Type: Review

References (163)

1. Buttmann M, Rieckmann P. Treating multiple sclerosis with monoclonal antibodies. Expert Rev. Neurother. 8 (3), 433-455 (2008). • Complements this article. It provides an introduction to multiple sclerosis (MS), the pharmacological class of therapeutic monoclonal antibodies in general, and to natalizumab, alemtuzumab, rituximab and daclizumab in particular. (Pubitemid 351480907)
2. Zecca C, Nessi F, Bernasconi E, Gobbi C. Ocular toxoplasmosis during natalizumab treatment. Neurology 73 (17), 1418-1419 (2009).
3. Stuve O, Wiendl H. Iatrogenic immunosuppression with biologics in MS: expecting the unexpected? Neurology 73 (17), 1346-1347 (2009).
4. Gutwinski S, Erbe S, Munch C, Janke O, Muller U, Haas J. Severe cutaneous Candida infection during natalizumab therapy in multiple sclerosis. Neurology 74 (6), 521-523 (2010).
5. Egli A, Infanti L, Dumoulin A et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J. Infect. Dis. 199 (6), 837-846 (2009).
6. Knowles WA, Pipkin P, Andrews N et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J. Med. Virol. 71 (1), 115-123 (2003). (Pubitemid 37121921)
7. Major EE. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu. Rev. Med. 61, 35-47 (2010). • Review by the head of the NIH progressive multifocal leukoencephalopathy (PML) reference laboratory on the pathogenesis of HIV-and immunotherapy-associated PML.
8. Rudick RA, Polman CH, O'Connor PW et al. Evaluation of natalizumab treatment on the presence of JC virus in blood and urine from multiple sclerosis patients. Presented at: 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Duesseldorf, Germany, 9-12 September 2009 (P883).
9. Dominguez-Mozo MI, Alvarez-Lafuente R, Garcia-Montojo M et al. JC virus in multiple sclerosis patients treated with natalizumab. Presented at: 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Duesseldorf, Germany, 9-12 September 2009 (P315).
10. Gorelik L, Goelz S, Sandrock AA. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N. Engl. J. Med. 361 (25), 2487-2488; author reply 2489-2490 (2009).
11. Chen Y, Bord E, Tompkins T et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N. Engl. J. Med. 361 (11), 1067-1074 (2009).
12. Sadiq SA, Puccio LM, Brydon EE. JCV detection in multiple sclerosis patients treated with natalizumab. J. Neurol. (2009) (Epub ahead of print).
13. Kappos L, Bates D, Hartung HP et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol. 6 (5), 431-441 (2007). (Pubitemid 46551850)
14. Berger JR, Miller CS, Mootoor Y, Avdiushko SA, Kryscio RJ, Zhu H. JC virus detection in bodily fuids: clues to transmission. Clin. Infect. Dis. 43 (1), e9-e12 (2006).
15. Marzocchetti A, Tompkins T, Clifford DB et al. Determinants of survival in progressive multifocal leukoencephalopathy. Neurology 73 (19), 1551-1558 (2009).
16. Du Pasquier RA, Kuroda MJ, Zheng Y, Jean-Jacques J, Letvin NL, Koralnik II. A prospective study demonstrates an association between JC virus-specifc cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 127 (Pt 9), 1970-1978 (2004). (Pubitemid 39150256)
17. Koralnik IJ, Du Pasquier RA, Kuroda MJ et al. Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specifc for a commonly recognized JC virus epitope. J. Immunol. 168 (1), 499-504 (2002).
18. Jilek S, Jaquiery E, Hirsch HH et al. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurol. 9 (3), 264-272 (2010).
19. Haghikia A, Pappas D, Pula B et al. Assessment of a possible bioenergetic marker of cellular immunocompetence in MS patients undergoing immunotherapy: longitudinal analyses. Presented at: 61st Annual Meeting of the American Academy of Neurology. Seattle, USA, 25 April-2 May 2009.
20. Varnier OE, McDermott JL, Giacomazzi CG et al. Non invasive surveillance of JCV reactivation in blood and urine from natalizumab treated MS patients, blood donors and immunocompromised patients identifes two PML cases in HIV and congenital immunodefciency patients. Presented at: 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Duesseldorf, Germany, 9-12 September 2009 (P889).
21. + T helper cell function in recently transplanted renal allograft patients undergoing tapering of their immunosuppressive drugs. Transplantation 56 (3), 590-596 (1993).
22. Kowalski R, Post D, Schneider MC et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin. Transplant. 17 (2), 77-88 (2003). (Pubitemid 36833776)
23. Molloy ES, Calabrese LL. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum. 60 (12), 3761-3765 (2009).
24. D'Arminio Monforte A, Cinque P, Mocroft A et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann. Neurol. 55 (3), 320-328 (2004). (Pubitemid 38292033)
25. Engsig FN, Hansen AB, Omland LH et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J. Infect. Dis. 199 (1), 77-83 (2009).
26. Koralnik II. New insights into progressive multifocal leukoencephalopathy. Curr. Opin. Neurol. 17 (3), 365-370 (2004). (Pubitemid 38720991)
27. Berger JR, Kaszovitz B, Post MJ, Dickinson G. Progressive multifocal leukoencephalopathy associated with human immunodefciency virus infection. A review of the literature with a report of sixteen cases. Ann. Intern. Med. 107 (1), 78-87 (1987). (Pubitemid 17098643)
28. De Luca A, Giancola ML, Ammassari A et al. The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fuid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy. J. Infect. Dis. 182 (4), 1077-1083 (2000).
29. Antinori A, Cingolani A, Lorenzini P et al. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J. Neurovirol. 9 (Suppl. 1), 47-53 (2003). (Pubitemid 36656471)
30. Riedel DJ, Pardo CA, McArthur J, Nath A. Therapy Insight: CNS manifestations of HIV-associated immune reconstitution infammatory syndrome. Nat. Clin. Pract. Neurol. 2 (10), 557-565 (2006). (Pubitemid 44445811)
31. McCombe JA, Auer RN, Maingat FG, Houston S, Gill MJ, Power C. Neurologic immune reconstitution infammatory syndrome in HIV/AIDS: outcome and epidemiology. Neurology 72 (9), 835-841 (2009).
32. Sidhu N, McCutchan JJ. Unmasking of PML by HAART: unusual clinical features and the role of IRIS. J. Neuroimmunol. 219 (1-2), 100-104 (2010).
33. Perumal J, Hreha S, Bao F et al. Postnatalizumab associated rebound or CNS immune reconstitution syndrome: clinical and MRI fndings. Presented at: 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Duesseldorf, Germany, 9-12 September 2009 (P418). • Provides evidence that CNS immune reconstitution infammatory syndrome after natalizumab cessation may occur in the absence of PML.
34. Linda H, von Heijne A, Major EO et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N. Engl. J. Med. 361 (11), 1081-1087 (2009).
35. Wenning W, Haghikia A, Laubenberger J et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N. Engl. J. Med. 361 (11), 1075-1080 (2009).
36. Carson KR, Focosi D, Major EO et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 10 (8), 816-824 (2009).
37. Carson KR, Evens AM, Richey EA et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113 (20), 4834-4840 (2009). • Largest series of rituximab-associated PML cases.
38. Molloy ES, Calabrese LL. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun. Rev. 8 (2), 144-146 (2008).
39. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. 353 (4), 375-381 (2005). (Pubitemid 41132342)
40. Kleinschmidt-DeMasters BK, Tyler KK. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon β-1a for multiple sclerosis. N. Engl. J. Med. 353 (4), 369-374 (2005).
41. Goodman AD, Rossman H, Bar-Or A et al. GLANCE: results of a Phase 2, randomized, double-blind, placebo-controlled study. Neurology 72 (9), 806-812 (2009).
42. O'Connor PW, Polman CH, Goodman AD et al. Effcacy and safety of natalizumab in the STRATA study. Presented at: 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Duesseldorf, Germany, 9-12 September 2009. •• STRATA study provides important information on the safety and effcacy of natalizumab redosing after a treatment gap.
43. Stuve O, Cravens PD, Frohman EM et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology 72 (5), 396-401 (2009). • Authors observed a normalization of immune cell counts and ratios in peripheral blood and CSF 14 months after natalizumab cessation.
44. Schiess N, Calabresi PP. Natalizumab: bound to rebound? Neurology 72 (5), 392-393 (2009).
45. Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BM, Polman CC. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 70 (13 Pt 2), 1150-1151 (2008). (Pubitemid 351464749)
46. Tubridy N, Behan PO, Capildeo R et al. The effect of anti-α4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 53 (3), 466-472 (1999).
47. Gold R, Hartung HP, Hohlfeld R et al. [Therapy of multiple sclerosis with monoclonal antibodies - results and recommendations of a workshop of the medical advisory board of the German Multiple Sclerosis Society]. Aktuelle Neurologie 36 (7), 334-344 (2009). • Group of German MS experts on the clinical use of natalizumab, facing PML cases in the post-marketing setting.
48. De Luca A, Ammassari A, Pezzotti P et al. Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. Aids 22 (14), 1759-1767 (2008).
49. Hou J, Major EE. The effcacy of nucleoside analogs against JC virus multiplication in a persistently infected human fet al. brain cell line. J. Neurovirol. 4 (4), 451-456 (1998). (Pubitemid 28395727)
50. Hall CD, Dafni U, Simpson D et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodefciency virus infection. AIDS Clinical Trials Group 243 Team. N. Engl. J. Med. 338 (19), 1345-1351 (1998). (Pubitemid 28216663)
51. Brickelmaier M, Lugovskoy A, Kartikeyan R et al. Identifcation and characterization of mefoquine effcacy against JC virus in vitro. Antimicrob. Agents Chemother. 53 (5), 1840-1849 (2009).
52. Elphick GF, Querbes W, Jordan JA et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 306 (5700), 1380-1383 (2004). (Pubitemid 39532516)
53. 2a receptor antagonists inhibit infection of human glial cells by JC virus. Virus Res. 132 (1-2), 97-103 (2008).
54. Lima MA, Auriel E, Wuthrich C, Borenstein NM, Koralnik II. Progressive multifocal leukoencephalopathy as a complication of hepatitis C virus treatment in an HIV-negative patient. Clin. Infect. Dis. 41 (3), 417-419 (2005). (Pubitemid 41022127)
55. Verma S, Cikurel K, Koralnik IJ et al. Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J. Infect. Dis. 196 (5), 709-711 (2007). (Pubitemid 47293853)
56. Bezabeh S, Flowers CM, Kortepeter C, Avigan M. Review article: clinically signifcant liver injury in patients treated with natalizumab (TYSABRI). Aliment. Pharmacol. Ther. (2010) (Epub ahead of print).
57. Golay J, Manganini M, Rambaldi A, Introna M. Effect of alemtuzumab on neoplastic B cells. Haematologica 89 (12), 1476-1483 (2004). (Pubitemid 39643515)
58. Mone AP, Cheney C, Banks AL et al. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raftdependent mechanism. Leukemia 20 (2), 272-279 (2006). (Pubitemid 43148665)
59. Smolewski P, Szmigielska-Kaplon A, Cebula B et al. Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells. Leuk. Lymphoma 46 (1), 87-100 (2005). (Pubitemid 40545566)
60. Zent CS, Secreto CR, LaPlant BR et al. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk. Res. 32 (12), 1849-1856 (2008).
61. Cox AL, Thompson SA, Jones JL et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur. J. Immunol. 35 (11), 3332-3342 (2005).
62. Thompson SA, Jones JL, Cox AL, Compston DA, Coles AA. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J. Clin. Immunol. 30 (1), 99-105 (2010).
63. Batten M, Groom J, Cachero TG et al. BAFF mediates survival of peripheral immature B lymphocytes. J. Exp. Med. 192 (10), 1453-1466 (2000).
64. Hu Y, Turner MJ, Shields J et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 128 (2), 260-270 (2009).
65. Wray S. A descriptive analysis of infectious adverse events in alemtuzumab-treated multiple sclerosis patients. Presented at: 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Düsseldorf, Germany, 9-12 September 2009 (P812).
66. Jones JL, Coles AA. Spotlight on alemtuzumab. Int. MS J. 16 (3), 77-81 (2009).
67. Chen F, Day SL, Metcalfe RA et al. Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with advanced human immunodefciency virus (HIV) disease. Medicine (Baltimore) 84 (2), 98-106 (2005). (Pubitemid 40418638)
68. Daikeler T, Tyndall A. Autoimmunity following haematopoietic stem-cell transplantation. Best Pract. Res. Clin. Haematol. 20 (2), 349-360 (2007). (Pubitemid 46585970)
69. Jubault V, Penfornis A, Schillo F et al. Sequential occurrence of thyroid autoantibodies and Graves' disease after immune restoration in severely immunocompromised human immunodefciency virus-1-infected patients. J. Clin. Endocrinol. Metab. 85 (11), 4254-4257 (2000). (Pubitemid 32055382)
70. Krupica T Jr, Fry TJ, Mackall CC. Autoimmunity during lymphopenia: a two-hit model. Clin. Immunol. 120 (2), 121-128 (2006).
71. Ettinger R, Kuchen S, Lipsky PP. Interleukin 21 as a target of intervention in autoimmune disease. Ann. Rheum. Dis. 67 (Suppl. 3), iii83-iii86 (2008).
72. Jones JL, Phuah CL, Cox AL et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J. Clin. Invest. 119 (7), 2052-2061 (2009). •• Identifes an immunological mechanism, potentially allowing the assessment of the risk of thyroid autoimmunity in alemtuzumab-treated MS patients to a clinically relevant extent.
73. Weetman A. Immune reconstitution syndrome and the thyroid. Best Pract. Res. Clin. Endocrinol. Metab. 23 (6), 693-702 (2009).
74. Coles AJ, Compston DA, Selmaj KW et al. Alemtuzumab vs. interferon p-1a in early multiple sclerosis. N. Engl. J. Med. 359 (17), 1786-1801 (2008).
75. Coles AA. Alemtuzumab treatment beneft is durable: primary effcacy outcomes of CAMMS223 at 4 years. Presented at: 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Düsseldorf, Germany, 9-12 September 2009.
76. Hirst CL, Pace A, Pickersgill TP et al. Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J. Neurol. 255 (2), 231-238 (2008).
77. Selmaj K. Immunogenicity of alemtuzumab treatment for relapsing-remitting multiple sclerosis: no effect on effcacy or safety. Presented at: 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Düsseldorf, Germany, 9-12 September 2009 (P811). • According to data from the CAMMS223 trial, anti-alemtuzumab antibodies do not reduce the effcacy of the drug, and are not associated with adverse effects.
78. Ooi JD, Holdsworth SR, Kitching AA. Advances in the pathogenesis of Goodpasture's disease: from epitopes to autoantibodies to effector T cells. J. Autoimmun. 31 (3), 295-300 (2008).
79. Coles AJ, Cox A, Le Page E et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J. Neurol. 253 (1), 98-108 (2006). (Pubitemid 43157395)
80. Pace AA, Zajicek JJ. Melanoma following treatment with alemtuzumab for multiple sclerosis. Eur. J. Neurol. 16 (4), e70-e71 (2009).
81. Hauser SL, Waubant E, Arnold DL et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl. J. Med. 358 (7), 676-688 (2008). •• Phase II trial demonstrated that B-cell depletion is a promising therapeutic concept in patients with relapsing-remitting MS. (Pubitemid 351240747)
82. Hawker K, O'Connor P, Freedman MS et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebocontrolled multicenter trial. Ann. Neurol. 66 (4), 460-471 (2009). •• Phase II/III trial suggested that B-cell depletion may be effective in younger patients with primary progressive MS and infammatory MRI disease activity.
83. Wolinsky JS, Narayana PA, O'Connor P et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann. Neurol. 61 (1), 14-24 (2007). (Pubitemid 46214240)
84. Wolinsky JS, Shochat T, Weiss S, Ladkani D. Glatiramer acetate treatment in PPMS: why males appear to respond favorably. J. Neurol. Sci. 286 (1-2), 92-98 (2009).
85. Bar-Or A, Calabresi PA, Arnold D et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, Phase I trial. Ann. Neurol. 63 (3), 395-400 (2008). (Pubitemid 351499869)
86. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BB. Revised diagnostic criteria for neuromyelitis optica. Neurology 66 (10), 1485-1489 (2006).
87. Bradl M, Misu T, Takahashi T et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann. Neurol. 66 (5), 630-643 (2009).
88. Cayrol R, Saikali P, Vincent T. Effector functions of antiaquaporin-4 autoantibodies in neuromyelitis optica. Ann. NY Acad. Sci. 1173, 478-486 (2009).
89. Kinoshita M, Nakatsuji Y, Kimura T et al. Neuromyelitis optica: passive transfer to rats by human immunoglobulin. Biochem. Biophys. Res. Commun. 386 (4), 623-627 (2009).
90. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64 (7), 1270-1272 (2005). (Pubitemid 40490534)
91. Jacob A, Weinshenker BG, Violich I et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch. Neurol. 65 (11), 1443-1448 (2008).
92. Kausar F, Mustafa K, Sweis G et al. Ocrelizumab: a step forward in the evolution of B-cell therapy. Expert Opin. Biol. Ther. 9 (7), 889-895 (2009).
93. van Meerten T, Hagenbeek A. CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma. Neth. J. Med. 67 (7), 251-259 (2009). • Well-arranged comparison of anti-CD20 monoclonal antibodies, including, but not limited to, rituximab, ocrelizumab and ofatumumab.
94. Genovese MC, Kaine JL, Lowenstein MB et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a Phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum. 58 (9), 2652-2661 (2008).
95. Morschhauser F, Marlton P, Vitolo U et al. Interim results of a Phase I/II study of ocrelizumab, a new humanised anti-CD20 antibody in patients with relapsed/refractory follicular non-hodgkin's lymphoma. Blood 110, 199A (2007).
96. van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the side-effects of rituximab treatment. Br. J. Haematol. 115 (4), 807-811 (2001).
97. Castillo J, Milani C, Mendez-Allwood D. Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. Expert Opin. Investig. Drugs 18 (4), 491-500 (2009).
98. Robak T. Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders. Curr. Opin. Mol. Ther. 10 (3), 294-309 (2008). • Comprehensive introduction to ofatumumab. (Pubitemid 351799281)
99. Coiffer B, Lepretre S, Pedersen LM et al. Safety and effcacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a Phase 1-2 study. Blood 111 (3), 1094-1100 (2008). (Pubitemid 351213387)
100. Traynor K. Ofatumumab approved for advanced CLL. Am. J. Health Syst. Pharm. 66 (23), 2062 (2009).
101. Hagenbeek A, Gadeberg O, Johnson P et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a Phase 1/2 trial. Blood 111 (12), 5486-5495 (2008).
102. Ostergaard M, Baslund B, Rigby W et al. Ofatumumab, a human CD20 monoclonal antibody, in the treatment of rheumatoid arthritis: early results from an ongoing, double-blind, randomized, placebocontrolled clinical trial. Presented at: ACR/ARHP 2007 Annual Scientifc Meeting. Boston, USA, 6-11 November 2007
103. Ostergaard M, Baslund B, Rigby W et al. Effcacy of ofatumumab in rheumatoid arthritis (RA) patients with inadequate response to one or more DMARDS: 48 weeks follow-up. Presented at: ACR/ARHP 2008 Annual Scientifc Meeting. San Francisco, CA, USA, 24-29 October 2008.
104. Teeling JL, French RR, Cragg MS et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104 (6), 1793-1800 (2004).
105. Teeling JL, Mackus WJ, Wiegman LJ et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 177 (1), 362-371 (2006).
106. Pawluczkowycz AW, Beurskens FJ, Beum PV et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX) : considerably higher levels of CDC are induced by OFA than by RTX. J. Immunol. 183 (1), 749-758 (2009).
107. Uchiyama S, Suzuki Y, Otake K et al. Development of novel humanized anti-CD20 antibodies based on affnity constant and epitope. Cancer Sci. 101 (1), 201-209 (2009).
108. Cragg MS, Morgan SM, Chan HT et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 101 (3), 1045-1052 (2003).
109. Bleeker WK, Munk ME, Mackus WJ et al. Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br. J. Haematol. 140 (3), 303-312 (2008).
110. Hawker K, O'Connor P, Freedman MS et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebocontrolled multicenter trial. Ann. Neurol. 66 (4), 460-471 (2009).
111. Bielekova B, Catalfamo M, Reichert-Scrivner S et al. Regulatory CD56 (bright) natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl Acad. Sci. USA 103 (15), 5941-5946 (2006).
112. Wynn D, Kaufman M, Montalban X et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study) : a Phase 2, randomised, double-blind, placebocontrolled, add-on trial with interferon β. Lancet Neurol. 9 (4), 381-390 (2010).
113. Sheridan J, Elkins J, Zhang Y et al. Expansion of CD56bright NK cells correlates with therapeutic response to daclizumab in multiple sclerosis. Presented at: 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Düsseldorf, Germany, 9-12 September 2009 (P430). • CHOICE trial confrmed previous findings that expansion of a regulatory natural killer cell population correlates with the therapeutic effect of daclizumab in MS patients. This cell population may therefore serve as an effcacy biomarker.
114. Oh U, Blevins G, Griffth C et al. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch. Neurol. 66 (4), 471-479 (2009).
115. Viglietta V, Baecher-Allan C, Weiner HL, Hafer DD. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199 (7), 971-979 (2004). (Pubitemid 38481088)
116. high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur. J. Immunol. 35 (11), 3343-3352 (2005). (Pubitemid 41672538)
117. Bielekova B, Howard T, Packer AN et al. Effect of anti-CD25 antibody daclizumab in the inhibition of infammation and stabilization of disease progression in multiple sclerosis. Arch. Neurol. 66 (4), 483-489 (2009).
118. Ali EN, Healy BC, Stazzone LA, Brown BA, Weiner HL, Khoury SS. Daclizumab in treatment of multiple sclerosis patients. Mult. Scler. 15 (2), 272-274 (2009).
119. Chien AL, Elder JT, Ellis CC. Ustekinumab: a new option in psoriasis therapy. Drugs 69 (9), 1141-1152 (2009).
120. Weber J, Keam SS. Ustekinumab. BioDrugs 23 (1), 53-61 (2009).
121. Korn T, Oukka M, Kuchroo V, Bettelli E. Th17 cells: effector T cells with infammatory properties. Semin. Immunol 19 (6), 362-371 (2007). (Pubitemid 351274046)
122. Leonardi CL, Kimball AB, Papp KA et al. Effcacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 1). Lancet 371 (9625), 1665-1674 (2008). (Pubitemid 351671883)
123. Papp KA, Langley RG, Lebwohl M et al. Effcacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371 (9625), 1675-1684 (2008). (Pubitemid 351671884)
124. Cua DJ, Sherlock J, Chen Y et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune infammation of the brain. Nature 421 (6924), 744-748 (2003). (Pubitemid 36227625)
125. Langrish CL, Chen Y, Blumenschein WM et al. IL-23 drives a pathogenic T cell population that induces autoimmune infammation. J. Exp. Med. 201 (2), 233-240 (2005). (Pubitemid 40189432)
126. Segal BM, Dwyer BK, Shevach EE. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J. Exp. Med. 187 (4), 537-546 (1998).
127. Segal BM, Shevach EE. IL-12 unmasks latent autoimmune disease in resistant mice. J. Exp. Med. 184 (2), 771-775 (1996).
128. + T cells via CD40 ligand. Proc. Natl Acad. Sci. USA 94 (2), 599-603 (1997).
129. Vaknin-Dembinsky A, Balashov K, Weiner HH. IL-23 is increased in dendritic cells in multiple sclerosis and downregulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J. Immunol. 176 (12), 7768-7774 (2006). (Pubitemid 43849078)
130. Lock C, Hermans G, Pedotti R et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8 (5), 500-508 (2002). (Pubitemid 34546753)
131. Woodroofe MN, Cuzner MM. Cytokine mRNA expression in infammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization. Cytokine 5 (6), 583-588 (1993).
132. Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LL. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a Phase II, double-blind, placebocontrolled, randomised, dose-ranging study. Lancet Neurol. 7 (9), 796-804 (2008). • IL-12/23 neutralization by ustekinumab failed to show a therapeutic effect in MS patients, which may shed new light on the pathogenesis of MS.
133. Longbrake EE, Racke MM. Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis? Expert Rev. Neurother. 9 (3), 319-321 (2009).
134. Mackay F, Schneider P. Cracking the BAFF code. Nat. Rev. Immunol. 9 (7), 491-502 (2009).
135. Khan WW. B cell receptor and BAFF receptor signaling regulation of B cell homeostasis. J. Immunol. 183 (6), 3561-3567 (2009).
136. Kikly K, Manetta J, Smith H, Wierda D, Witcher D. Characterization of LY2127399, a neutralizing antibody for BAFF. Presented at: ACR/ARHP 2009 Annual Scientifc Meeting. PA, USA, 17-21 October 2009.
137. Genovese MC, Mociran E, Biagini M, Bojin S, Sloan-Lancaster J. Phase 2
138. Magliozzi R, Columba-Cabezas S, Serafni B, Aloisi F. Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J. Neuroimmunol. 148 (1-2), 11-23 (2004). (Pubitemid 38229554)
139. Huntington ND, Tomioka R, Clavarino C et al. A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cellmediated and humoral immune responses. Int. Immunol. 18 (10), 1473-1485 (2006). (Pubitemid 44446825)
140. Krumbholz M, Theil D, Derfuss T et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J. Exp. Med. 201 (2), 195-200 (2005). (Pubitemid 40189428)
141. Mackay F, Sierro F, Grey ST, Gordon TT. The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr. Dir. Autoimmun. 8, 243-265 (2005).
142. Thangarajh M, Gomes A, Masterman T, Hillert J, Hjelmstrom P. Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis. J. Neuroimmunol. 152 (1-2), 183-190 (2004). (Pubitemid 38829716)
143. Krumbholz M, Faber H, Steinmeyer F et al. Interferon-βincreases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 131 (Pt 6), 1455-1463 (2008). (Pubitemid 351806460)
144. Schwid SR, Goodman AD, Mattson DD. Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon β-1b. Arch. Neurol. 54 (9), 1169-1190 (1997).
145. Rotondi M, Mazziotti G, Biondi B et al. Long-term treatment with interferon-βtherapy for multiple sclerosis and occurrence of Graves' disease. J. Endocrinol. Invest. 23 (5), 321-324 (2000). (Pubitemid 30426552)
146. Caraccio N, Dardano A, Manfredonia F et al. Long-term follow-up of 106 multiple sclerosis patients undergoing interferon-β1a or 1b therapy: predictive factors of thyroid disease development and duration. J. Clin. Endocrinol. Metab. 90 (7), 4133-4137 (2005). (Pubitemid 41058187)
147. Bergamaschi R, Montomoli C. Melanoma in multiple sclerosis treated with natalizumab: causal association or coincidence? Mult. Scler. 15 (12), 1532-1533 (2009).
148. Ismail A, Kemp J, Sharrack B. Melanoma complicating treatment with natalizumab (tysabri) for multiple sclerosis. J. Neurol. 256 (10), 1771-1772 (2009).
149. Mullen JT, Vartanian TK, Atkins MM. Melanoma complicating treatment with natalizumab for multiple sclerosis. N. Engl. J. Med. 358 (6), 647-648 (2008). (Pubitemid 351214309)
150. Schweikert A, Kremer M, Ringel F et al. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann. Neurol. 66 (3), 403-406 (2009).
151. Martinelli V, Radaelli M, Straff L, Rodegher M, Comi G. Mitoxantrone: benefts and risks in multiple sclerosis patients. Neurol. Sci. 30 (Suppl. 2), S167-S170 (2009).
152. Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NN. Daclizumab Phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 69 (8), 785-789 (2007). (Pubitemid 47300936)
153. Kappos L, Radue EW, O'Connor P et al. A placebo-controlled trial of oral fngolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362 (5), 387-401 (2010).
154. Giovannoni G, Comi G, Cook S et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N. Engl. J. Med. 362 (5), 416-426 (2010).
155. Cohen JA, Barkhof F, Comi G et al. Oral fngolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362 (5), 402-415 (2010).
156. Sipe JJ. Cladribine for multiple sclerosis: review and current status. Expert Rev. Neurother. 5 (6), 721-727 (2005). (Pubitemid 41679640)
157. Cook S, Vermersch P, Comi G et al. Safety and tolerability of cladribine tablets in relapsing-remitting multiple sclerosis during the 96-week, Phase III, doubleblind, placebo-controlled CLARITY study. Presented at: 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Duesseldorf, Germany, 9-12 September 2009.
158. Kappos L, Antel J, Comi G et al. Oral fngolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 355 (11), 1124-1140 (2006). (Pubitemid 44394919)
159. O'Connor PW, Li D, Freedman MS et al. A Phase II study of the safety and effcacy of terifunomide in multiple sclerosis with relapses. Neurology 66 (6), 894-900 (2006). (Pubitemid 43739766)
160. Freedman M, Wolinsky JS, Byrnes WJ et al. Oral Terifunomide or placebo added to interferon β for 6 months in patients with relapsing multiple sclerosis: safety and effcacy results. Presented at: 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Duesseldorf, Germany, 9-12 September 2009.
161. Comi G, Pulizzi A, Rovaris M et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebocontrolled Phase IIb study. Lancet 371 (9630), 2085-2092 (2008). (Pubitemid 351842581)
162. Kappos L, Gold R, Miller DH et al. Effcacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled Phase IIb study. Lancet 372 (9648), 1463-1472 (2008). (Pubitemid 351842581)
163. Klawiter EC, Cross AH, Naismith RR. The present effcacy of multiple sclerosis therapeutics: is the new 66% just the old 33%? Neurology 73 (12), 984-990 (2009).